GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data

摘要: BACKGROUND: Cancer survival rates in young women are improving due to progress treatment. This includes aggressive chemotherapy, a treatment that often poses threat fertility. GnRH agonists were proposed as ovarian protectors during gonadotoxic therapies. study was undertaken order determine the clinical evidence concerning this issue. METHODS: The medical literature searched for studies reported on function after administration of concomitant with chemotherapy. Twelve met predetermined selection criteria. RESULTS: Data obtained 579 who received Among 345 agonist co-treatment, preserved 91% and 9% had premature failure. In 234 did not receive 41% failed 59%. Only two randomized. control groups differed several important characteristics: follow-up times equal, different protocols utilized end-points poorly defined inconsistent between studies. CONCLUSIONS: effectiveness fertility-preserving agents is debatable. A thorough search has found insufficient show co-treatment effective protecting ovary from damage large randomized controlled trial adequate needed.